Form 4: Director Nancy Ryan Gray Receives Equity Grant at Ligand

Director Nancy Ryan Gray was granted 836 restricted stock units and 2,938 stock options as part of an annual board compensation package.

Summary

• Director Nancy Ryan Gray acquired 836 restricted stock units (RSUs) on June 5, 2026.
• Director Nancy Ryan Gray was granted 2,938 non-qualified stock options with an exercise price of $237 per share.
• The equity grants were awarded by the Board of Directors during the annual meeting.
• Both the RSUs and the stock options are set to vest on the earlier of the next annual stockholders meeting or the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant market sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized annual equity grant process for board members.

Negatives

• Dilutive impact of new equity grants, though minor in scale.

Risks

• Market price volatility affecting the value of the granted options.
• Potential for future dilution if additional equity grants are issued to board members.

Future Outlook

The equity grants vest on the earlier of the next annual meeting or the first anniversary of the grant date, aligning director tenure with company performance.

Industry Context

StockSavvy.ai notes that annual equity grants to board members are a standard corporate governance practice in the biotechnology sector to ensure long-term alignment between directors and shareholders.

Comparison to Industry Standards

• The grant of RSUs and options is consistent with standard compensation packages for non-employee directors in mid-cap pharmaceutical companies.
• Vesting schedules of one year are standard practice for annual director equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution from new equity issuance.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of the RSUs and options on or before June 5, 2027.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Trading, Equity Compensation, Director Compensation